We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+46.67%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.04B
AUM Growth
+$235M
Cap. Flow
-$27.9M
Cap. Flow %
-2.69%
Top 10 Hldgs %
62.46%
Holding
79
New
20
Increased
8
Reduced
18
Closed
12

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$12.9M
2
NVO
Novo Nordisk
NVO
+$12.2M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.92M
4
HALO icon
Halozyme
HALO
+$6.5M
5
BPMC
Blueprint Medicines
BPMC
+$5.31M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$43.8M
2
SNY icon
Sanofi
SNY
+$14.2M
3
GILD icon
Gilead Sciences
GILD
+$13.3M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$11.3M
5
INCY icon
Incyte
INCY
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 83.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TGTX icon
51
TG Therapeutics
TGTX
$8.58B
$2.83M 0.27%
+351,811
New +$1.9M
KYNB
52
PUT
Kyntra Bio
KYNB
$28.5M
$2.72M 0.26%
+2,000
New +$2.71M
OTIC
53
DELISTED
Otonomy, Inc.
OTIC
$2.69M 0.26%
1,023,865
– –
LKFT
54
PUT
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$2.35M 0.23%
+20,000
New +$2.02M
ARQL
55
DELISTED
Arqule Inc
ARQL
$1.7M 0.16%
+355,725
New +$1.37M
CLVS
56
DELISTED
Clovis Oncology, Inc.
CLVS
$1.65M 0.16%
66,635
-221,134
-77% -$5.54M
BMRN icon
57
BioMarin Pharmaceuticals
BMRN
$11.5B
$1.64M 0.16%
18,494
-122,048
-87% -$11.3M
SNDX icon
58
Syndax Pharmaceuticals
SNDX
$1.84B
$1.12M 0.11%
213,359
-136,751
-39% -$780K
PDSB icon
59
PDS Biotechnology
PDSB
$38.1M
$1.05M 0.1%
142,635
-1
-0% -$8
PTLA
60
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$1.04M 0.1%
+30,000
New +$866K
APLS
61
DELISTED
Apellis Pharmaceuticals
APLS
$967K 0.09%
49,580
– –
RVLP
62
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
$911K 0.09%
253,089
– –
ADVM
63
DELISTED
Adverum Biotechnologies
ADVM
$835K 0.08%
+15,924
New +$644K
IMGN
64
CALL
DELISTED
Immunogen Inc
IMGN
$406K 0.04%
+150,000
New +$650K
HSTO
65
CALL
DELISTED
Histogen Inc. Common Stock
HSTO
$162K 0.02%
+750
New +$302K
GILD icon
66
Gilead Sciences
GILD
$161B
– –
-213,331
Closed -$13.3M
PBYI icon
67
Puma Biotechnology
PBYI
$406M
– –
-190,627
Closed -$5.82M
PCRX icon
68
Pacira BioSciences
PCRX
$1.02B
– –
-16,994
Closed -$731K
RIGL icon
69
Rigel Pharmaceuticals
RIGL
$680M
– –
-338,217
Closed -$7.78M
SNY icon
70
Sanofi
SNY
$104B
– –
-327,175
Closed -$14.2M
SRPT icon
71
Sarepta Therapeutics
SRPT
$1.66B
– –
-48,894
Closed -$5.34M
IMGN
72
DELISTED
Immunogen Inc
IMGN
– –
-447,075
Closed -$1.94M
EPZM
73
DELISTED
Epizyme, Inc
EPZM
– –
-563,655
Closed -$3.47M
HSTO
74
DELISTED
Histogen Inc. Common Stock
HSTO
– –
-3,191
Closed -$1.29M
FPRX
75
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-315,344
Closed -$2.93M
1 2
3
4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q1 2019 Portfolio in Review

As of Q1 2019, Sofinnova Investments held 79 positions worth $1.04B, up 29% from $803M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Sofinnova Investments's Q1 2019 filing shows 20 new, 8 increased, 18 reduced and 12 closed positions. Its largest new stake was Allergan plc: 88,665 shares worth $13M. The largest sale was Ascendis Pharma A/S, an estimated $43.8M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 91% a quarter earlier.

  • Sofinnova Investments's largest Q1 2019 buy was Allergan plc: 88,665 shares worth $13M.
  • Sofinnova Investments added most to AnaptysBio in Q1 2019, an estimated $5.03M increase.
  • Sofinnova Investments's biggest Q1 2019 reduction was Ascendis Pharma A/S, cutting an estimated $43.8M.
  • Sofinnova Investments fully exited Sanofi in Q1 2019, selling an estimated $14.2M.
  • Sofinnova Investments's ten largest holdings make up 62% of its $1.04B portfolio in Q1 2019.
  • Sofinnova Investments opened 20 new positions and closed 12 in Q1 2019.
  • Sofinnova Investments's portfolio value rose 29% quarter-over-quarter to $1.04B.

Based on Sofinnova Investments's 13F filing for Q1 2019, filed 15 May 2019.